{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:57:28Z","timestamp":1789502248582,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to examine trends in valproate use among women of childbearing potential (WCBP) aged 16\u201344\u2009years in Ireland following two European\u2010directed regulatory interventions in December 2014 and April 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a repeated cross\u2010sectional study using monthly national pharmacy claims data, to examine trend changes in the prevalence of valproate use among WCBP pre and post two separate regulatory events in December 2014 and April 2018. Annual population estimates from the Central Statistics Office were used to calculate the prevalence rate per 1000 eligible women. Segmented regression analysis of interrupted time series with negative binomial regression was used to examine rates for WCBP aged 16\u201344\u2009years, and by 10\u2010year age groups. Prevalence ratios (PR) are presented with 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among WCBP aged 16\u201344\u2009years, there was no statistically significant change in the month\u2010to\u2010month prevalence ratio in the post\u2010 compared to pre\u2010December 2014 intervention period. A significant decline was, however, observed in the post\u2010, compared to pre\u2010April 2018 intervention period (PR\u00a0=\u00a00.998, [95% CIs: 0.996, 1.000]; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.029). Among those aged 16\u201324\u2009years, a significant decreasing trend in the month\u2010to\u2010month prevalence ratio was found in the post\u2010 compared to pre\u2010December 2014 intervention period (PR\u00a0=\u00a00.991, [95% CIs: 0.984, 0.998];<jats:italic>p<\/jats:italic>\u2009&lt;0.01). A marginal effect was observed in the post\u2010 compared to pre\u2010April 2018 intervention period for those aged 25\u201334\u2009years (PR\u00a0=\u00a00.996, [95% CIs: 0.992, 1.000]; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.048).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although no evidence of change was observed following the December 2014 intervention period, a significant decline in the prevalence ratio of valproate use was observed after the 2018 intervention, which may reflect the introduction of the most recent contraindication measures.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5427","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T07:33:53Z","timestamp":1647243233000},"page":"661-669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Valproate utilisation trends among women of childbearing potential in Ireland between 2014 and 2019: A drug utilisation study using interrupted time series"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-8326","authenticated-orcid":false,"given":"John E.","family":"Hughes","sequence":"first","affiliation":[{"name":"Division of Population Health Sciences Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Buckley","sequence":"additional","affiliation":[{"name":"Health Products Regulatory Authority  Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace Dublin 2 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Looney","sequence":"additional","affiliation":[{"name":"Health Products Regulatory Authority  Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace Dublin 2 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Curran","sequence":"additional","affiliation":[{"name":"Health Products Regulatory Authority  Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace Dublin 2 Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Mullooly","sequence":"additional","affiliation":[{"name":"Division of Population Health Sciences Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[{"name":"Division of Population Health Sciences Royal College of Surgeons in Ireland  Dublin Ireland"},{"name":"Data Science Centre, Division of Population Health Sciences Royal College of Surgeons in Ireland  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"European Medicines Agency. Valproate and related substances. Article\u201031 referral \u2010 PRAC assessment report 2014.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-related-substances-article-31-referral-prac-assessment-report_en.pdf(Accessed 1 June 2021)."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.08.006"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"},{"issue":"10","key":"e_1_2_10_5_1","first-page":"14","article-title":"Valproate for acute mania","volume":"10","author":"Jochim J","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001304"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.022"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70103-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02668.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.176990"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803531"},{"key":"e_1_2_10_12_1","unstructured":"European Medicines Agency. Valproate and related substances. Article\u201031 referral \u2010 CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. 2014https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate\u2010related\u2010substances\u2010article\u201031\u2010referral\u2010cmdh\u2010agrees\u2010strengthen\u2010warnings\u2010use\u2010valproate_en.pdf(Accessed 1 June 2021)."},{"key":"e_1_2_10_13_1","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Etude observationnelle ANSM\u2010CNAMTS de l'exposition \u00e0 l'acide valpro\u00efque et ses d\u00e9riv\u00e9s au cours de la grossesse 2016.https:\/\/ansm.sante.fr\/Dossiers\/Valproate\u2010et\u2010derives\/Valproate\u2010et\u2010derives\/(offset)\/0(Accessed 1 June 2021)."},{"key":"e_1_2_10_14_1","unstructured":"European Medicines Agency. Valproate Article\u201031 referral \u2010 PRAC recommends new measures to avoid valproate exposure in pregnancy. 2018.https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate\u2010article\u201031\u2010referral\u2010prac\u2010recommends\u2010new\u2010measures\u2010avoid\u2010valproate\u2010exposure\u2010pregnancy_en.pdf(Accessed 1 June 2021)."},{"key":"e_1_2_10_15_1","unstructured":"The Health Products Regulatory Authority. Direct Healthcare Professional Communication for Prescribers \u2013 April 2018. 2018.https:\/\/www.hpra.ie\/docs\/default\u2010source\/Safety\u2010Notices\/important\u2010safety\u2010information\u2010for\u2010prescribers\u2010\u2010\u2010valproate\u2010(epilim).pdf?sfvrsn=0(Accessed 1 June 2021)."},{"key":"e_1_2_10_16_1","unstructured":"The Health Products Regulatory Authority. Direct Healthcare Professional Communication for Pharmacists \u2013 April 2018. 2018https:\/\/www.hpra.ie\/docs\/default\u2010source\/Safety\u2010Notices\/important\u2010safety\u2010information\u2010for\u2010pharmacists\u2010\u2010\u2010valproate\u2010(epilim).pdf?sfvrsn=0(Accessed 1 June 2021)."},{"key":"e_1_2_10_17_1","unstructured":"The Health Products Regulatory Authority IrelandValproate (Epilim) \u2013 Communicationshttp:\/\/www.hpra.ie\/homepage\/medicines\/special\u2010topics\/valproate\u2010(epilim)\/valproate\u2010(epilim)\u2010communications(Accessed 1 June 2021)."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.12.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317368"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.01.019"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13610"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12228"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4881"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_10_26_1","unstructured":"The Central Statistics Office. Vital Statistics Annual Report 2017.https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p\u2010vsar\/vitalstatisticsannualreport2017\/births2017\/(Accessed 1 June 2021)."},{"key":"e_1_2_10_27_1","unstructured":"The Health Products Regulatory Authority. Guide for Healthcare Professionals. 2018.http:\/\/www.hpra.ie\/docs\/default-source\/default-document-library\/epilim-hcp-guide_june-2018.pdf?sfvrsn=0(Accessed 1 June 2021)."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2310-7"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.01.004"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1933429"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5166"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.07.001"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyy135"},{"key":"e_1_2_10_34_1","unstructured":"BurkeP. Circular No: 025\/13 Re: Administration of the Long Term Illness Scheme 2013https:\/\/www.hse.ie\/eng\/staff\/pcrs\/circulars\/pharmacy\/prescription%20charges%202013.pdf(Accessed 1 June 2021)."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5427","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T22:21:16Z","timestamp":1693002076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/pds.5427"],"URL":"https:\/\/doi.org\/10.1002\/pds.5427","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2021-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}